Is hantavirus deadly? The short answer is: it depends entirely on which strain you have contracted and where you receive care. At one extreme, Puumala virus — the most common hantavirus in Europe — has a case fatality rate below 1%. At the other extreme, Andes virus and Sin Nombre virus kill roughly 35–40% of those infected, even in well-equipped hospitals.
The 2026 MV Hondius outbreak, which has caused 3 deaths among 10 confirmed cases as of 13 May 2026, sits at the lethal end of that spectrum — a 30% case fatality rate consistent with Andes virus historical data.
The Headline Numbers
| Strain | Disease | Region | Case Fatality Rate |
|---|---|---|---|
| Sin Nombre virus | HPS | USA, Canada | 36–38% |
| Andes virus | HPS | Argentina, Chile, 2026 cruise cluster | 35–40% |
| Black Creek Canal virus | HPS | USA (Florida) | ~35% |
| Bayou virus | HPS | USA (Gulf Coast) | ~35% |
| Puumala virus | HFRS | Europe (Scandinavia, central Europe) | <1% |
| Dobrava virus | HFRS | Balkans | 5–12% |
| Seoul virus | HFRS | Global (rat-associated) | <1% |
| Hantaan virus | HFRS | Asia (Korea, China, Russia) | 1–15% |
The split between HPS (Hantavirus Pulmonary Syndrome) and HFRS (Haemorrhagic Fever with Renal Syndrome) largely determines severity. HPS strains attack the lungs and are far more lethal. HFRS strains target the kidneys and are generally survivable with supportive care.
Why Is Hantavirus So Deadly for HPS Strains?
The lethality of hantavirus pulmonary syndrome is not primarily due to the virus destroying tissue directly. It is an immunopathological process — the immune response itself causes the damage.
When Andes or Sin Nombre virus infects pulmonary capillary endothelial cells, it triggers a massive immune cascade. T-cells and cytokines flood the lungs. Capillary permeability increases dramatically. Fluid pours into the alveoli — the tiny air sacs where oxygen exchange occurs. The lungs fill with fluid while the patient is still conscious and aware.
This process can go from mild breathlessness to complete respiratory failure in under 24 hours. No antiviral drug reliably stops it. Ribavirin, the only antiviral studied in HPS, showed no survival benefit in a randomised trial for established HPS (though it may have benefit in early Andes virus infection).
The only treatment is supportive: mechanical ventilation to maintain oxygenation and, increasingly, ECMO (extracorporeal membrane oxygenation) to bypass the failing lungs entirely while the body resolves the inflammation.
The Biggest Factor: Speed of Diagnosis
The case fatality rate for hantavirus HPS has declined significantly over the decades as clinicians have learned to recognise the disease earlier. In the first US Sin Nombre outbreak (1993, Four Corners), the fatality rate exceeded 70% — largely because the disease was unrecognised and patients arrived in extremis.
By 2010–2020, with better awareness, the US CFR had fallen to approximately 36%. The improvement is almost entirely attributable to earlier ICU admission, before patients develop refractory shock.
The critical window is the prodromal-to-cardiopulmonary transition. Patients admitted to ICU during the prodromal phase — before respiratory failure — have survival rates exceeding 70%. Patients who arrive in cardiopulmonary failure have survival rates below 50%.
This is why disclosure of exposure history is so important. A patient who says “I cleaned out a mouse-infested cabin last month” when presenting with fever and myalgia will be investigated for hantavirus. One who does not mention the exposure will be treated for flu and sent home — and may return in respiratory arrest.
ECMO: The Treatment That Changed Outcomes
The most significant advance in hantavirus treatment in the past decade is the expanded use of ECMO at specialised centres. ECMO pumps blood out of the body, oxygenates it through an artificial membrane, and returns it — bypassing the flooded lungs entirely for days or weeks while the immune response resolves.
Studies from the University of New Mexico, a major referral centre for hantavirus, show ECMO survival rates for HPS approaching 70–75% in selected patients — roughly double the historical pre-ECMO rate.
The catch: ECMO is only available at specialised tertiary centres. It requires a cardiac surgery team, perfusionists, and 24/7 expertise. In rural areas of the US Southwest where hantavirus is most common, ECMO capability may be hours away by air transport.
In the 2026 Hondius outbreak, ECMO has been deployed for at least two of the three critical cases.
Does Where You Live Determine Whether You Survive?
Bluntly: yes, to a significant degree. The same patient with the same stage of Andes virus HPS will have better survival odds in a centre with ECMO capability than in a hospital without it.
This creates stark disparities:
- Argentina: Andes virus has been endemic for decades. Argentina has developed national protocols and referral pathways, but rural areas in Patagonia — where most cases occur — have limited ICU capacity. Argentina’s historical CFR of 35–40% reflects this mix.
- USA: Strong hospital infrastructure but geographic maldistribution of ECMO centres. The CDC monitors cases actively. CFR ~36%.
- Europe (2026 Hondius cases): European patients in the Hondius cluster were admitted to tertiary hospitals in Amsterdam, Paris, and London — all with ECMO capability. Two of the three deaths occurred before ECMO could be initiated.
- New Zealand (2026): Auckland City Hospital has ECMO capability. The NZ case identified on 12 May is in ICU.
Is Hantavirus Deadly to Everyone Equally?
No. Several factors affect individual risk:
Age: Children appear to have lower CFR than adults, though HPS in children is well-documented. Adults aged 20–50 account for most severe cases.
Immune status: Paradoxically, a vigorous immune response — seen in young, healthy adults — may cause more lung damage than a weaker response. This is similar to the 1918 influenza pattern.
Time to presentation: The single largest modifiable variable. Early presentation = better survival.
Comorbidities: Diabetes, obesity, and pre-existing cardiovascular disease worsen outcomes, as with most severe respiratory illness.
Strain: See the table above. Puumala is rarely fatal; Andes and Sin Nombre are lethal without ICU care.
The 2026 MV Hondius Data
As of 13 May 2026, the Hondius cluster shows:
- 10 confirmed cases
- 3 deaths (30% CFR — within the historical Andes virus range)
- 7 survivors, 3 of whom remain in ICU
- All three deaths occurred in patients who presented late or had delayed diagnosis across international borders
The international nature of the outbreak — cases in 8 countries presenting to hospitals with varying levels of hantavirus awareness — likely contributed to some delayed diagnoses.
The Bottom Line
Hantavirus is among the most lethal viral pathogens a person can encounter in everyday life — but only certain strains, and only if care is delayed. Early recognition, rapid ICU admission, and access to ECMO are the three variables that most determine whether a patient lives or dies.
If you have potential exposure, the question is not “is hantavirus deadly?” — it is “how quickly can I get evaluated?” That question has a much better answer.
For real-time case tracking, see our global hantavirus map →
Explore HantavirusMap